Effectiveness of matching human leukocyte antigens
Effectiveness of matching human leukocyte antigens (HLA) in corneal transplantation: a scientific overview protocol
Background: Corneal transplantation is probably the most steadily carried out transplantation within the UK. Regardless of this, the therapeutic worth of matching human leukocyte antigen (HLA) subtypes for transplanted corneas stays controversial. Ocular immune privilege was initially deemed to render matching pointless; nevertheless, extra lately, matching has demonstrated improved outcomes together with graft success, amongst others. This systematic overview goals to guage the effectiveness of main and minor antigen matching on graft outcomes in corneal transplantation.
Strategies: Normal systematic overview methodology can be used to determine, choose and extract knowledge from observational research and medical trials assessing the results of HLA matching on corneal graft outcomes. Bibliographic databases (Cochrane Library, EMBASE, MEDLINE, Net of Science, Scopus), medical trial registers, summary and convention proceedings, along with dissertation, thesis and gray literature can be searched. Neither date of publication nor language can be restricted, and non-English articles can be translated the place obligatory. The first end result can be to evaluate corneal graft success for various levels of HLA matching/mismatching.
The exact finish end result measure varies amongst research and contains graft rejection, immunoreaction, failure and survival. Subsequently, knowledge can be extracted throughout all related end result parameters and grouped for subsequent statistical exams. Danger of bias evaluation can be accomplished, acceptable to every examine design. Research choice, knowledge extraction and threat of bias evaluation can be independently accomplished by two reviewers. Knowledge can be tabulated, and a story synthesis introduced. Meta-analysis can be carried out the place there may be ample homogeneity between research to warrant its efficient completion. Subgroup and sensitivity evaluation can be undertaken if acceptable.
Dialogue: Many research have investigated the effectiveness of HLA matching for corneal transplantation. A scientific overview is required to collate and analyse this proof. Findings of this systematic overview might kind the premise of evidence-based suggestions on pre-operative HLA typing and matching of corneal grafts for transplantation.
Scl-70 Antigen |
|||
| MBS318129-5x02mg | MyBiosource | 5x0.2mg | EUR 5580 |
Cow Scl-70 Antigen |
|||
| abx069937-10g | Abbexa | 10 g | Ask for price |
Cow Scl-70 Antigen |
|||
| abx069937-5g | Abbexa | 5 g | EUR 1750 |
Rabbit Scl-70 Antigen |
|||
| abx069936-25g | Abbexa | 25 g | EUR 1862.5 |
Scl-70 Antigen Antibody |
|||
| abx022697-2ml | Abbexa | 2 ml | EUR 594 |
Scl-70 Antigen Antibody |
|||
| abx022697-400l | Abbexa | 400 µl | Ask for price |
Scl-70 Antigen Antibody |
|||
| abx022697-80l | Abbexa | 80 µl | EUR 575 |
Scl-70 Antigen Protein |
|||
| abx069936-1000Units | Abbexa | 1000 Units | EUR 1846.8 |
Scl-70 Antigen Protein |
|||
| abx069937-02mg | Abbexa | 0.2 mg | EUR 1296 |
OPMA04225-200UG - Scl-70 Antigen Protein |
|||
| OPMA04225-200UG | Aviva Systems Biology | 0.2MG | EUR 1399 |
OPEF01639-1MG - Recombinant SCL-70 Antigen |
|||
| OPEF01639-1MG | Aviva Systems Biology | 1mg | EUR 1683 |
Borrelia Afzelii Antigen |
|||
| NAT41583-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
|||
Borrelia Afzelii Antigen |
|||
| NAT41583-500 | The Native Antigen Company | 0.5 | EUR 1187.13 |
|
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
|||
Borrelia Garinii Antigen |
|||
| NAT41584-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
|||
Borrelia Garinii Antigen |
|||
| NAT41584-500 | The Native Antigen Company | 0.5 | EUR 1187.13 |
|
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
|||
Brucella Abortus Antigen |
|||
| NAT41599-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Brucella abortus lysate, produced by fermentation. |
|||
Brucella Abortus Antigen |
|||
| NAT41599-500 | The Native Antigen Company | 0.5 | EUR 1187.13 |
|
Description: Brucella abortus lysate, produced by fermentation. |
|||
Candida Albicans Antigen |
|||
| NAT41601-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Candida albicans is grown on solid medium, washed, disrupted and subjected to an extraction process. The antigen consists of cytoplasmic and cell wall components. |
|||
Candida Albicans Antigen |
|||
| NAT41601-500 | The Native Antigen Company | 0.5 | EUR 1187.13 |
|
Description: Candida albicans is grown on solid medium, washed, disrupted and subjected to an extraction process. The antigen consists of cytoplasmic and cell wall components. |
|||
Canine Parvovirus Antigen |
|||
| NAT41594-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Canine Parvovirus, produced in CRFK cells. |
|||
Canine Coronavirus Antigen |
|||
| NAT41590-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Canine Coronavirus produced in A-72 cells. |
|||
Feline Calicivirus Antigen |
|||
| NAT41595-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Feline Calicivirus produced in FC 3TG cells. |
|||
Helicobacter Pylori Antigen |
|||
| NAT41603-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Bacteria are cultured on solid medium, harvested, washed and solubilised. The antigen is partially purified by detergent extraction and centrifugation. |
|||
Helicobacter Pylori Antigen |
|||
| NAT41603-500 | The Native Antigen Company | 0.5 | EUR 1187.13 |
|
Description: Bacteria are cultured on solid medium, harvested, washed and solubilised. The antigen is partially purified by detergent extraction and centrifugation. |
|||
Campylobacter Jejuni Antigen |
|||
| NAT41600-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Campylobacter jejuni is cultured on solid medium. This antigen is a partially purified detergent extract of the membrane fraction. The main component is an outer membrane protein, approximately 45 kDa in SDS-PAGE. |
|||
Campylobacter Jejuni Antigen |
|||
| NAT41600-500 | The Native Antigen Company | 0.5 | EUR 1187.13 |
|
Description: Campylobacter jejuni is cultured on solid medium. This antigen is a partially purified detergent extract of the membrane fraction. The main component is an outer membrane protein, approximately 45 kDa in SDS-PAGE. |
|||
Chlamydia Trachomatis Antigen |
|||
| CT022-1000 | The Native Antigen Company | 1.0 | EUR 382.41 |
|
Description: Chlamydia trachomatis antigens from clarified cell lysate. |
|||
Mycoplasma Pneumoniae Antigen |
|||
| MP901-1000 | The Native Antigen Company | 1.0 | EUR 1019.75 |
|
Description: Mycoplasma pneumoniae whole organisms that have been purified and detergent treated to enrich antigenic proteins and decrease background. |
|||
Mycoplasma Pneumoniae Antigen |
|||
| MP901-200 | The Native Antigen Company | 0.2 | EUR 272.96 |
|
Description: Mycoplasma pneumoniae whole organisms that have been purified and detergent treated to enrich antigenic proteins and decrease background. |
|||
Neisseria Gonorrhoeae Antigen |
|||
| NG01-1000 | The Native Antigen Company | 1.0 | EUR 382.41 |
|
Description: Homogenised lysate of pure bacteria. |
|||
Echovirus Antigen, Recombinant |
|||
| REC31776-100 | The Native Antigen Company | 0.1 | EUR 279.4 |
|
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus |
|||
Echovirus Antigen, Recombinant |
|||
| REC31776-500 | The Native Antigen Company | 0.5 | EUR 1053.23 |
|
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus |
|||
Trichomonas Vaginalis Antigen |
|||
| TV01-1000 | The Native Antigen Company | 1.0 | EUR 424.9 |
|
Description: Washed & lysed suspension of whole protozoa |
|||
Scl-70 |
|||
| GWB-E5CE57 | GenWay Biotech | 0.2 mg | Ask for price |
Scl-70 |
|||
| MBS634416-1000Units | MyBiosource | 1000Units | EUR 1735 |
Scl-70 |
|||
| MBS634416-5x1000Units | MyBiosource | 5x1000Units | EUR 7580 |
Echinococcus Granulosus Antigen |
|||
| NAT41602-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Echinococcus granulosus material is derived from bovine hydatid cyst as sterile filtered cyst fluid. |
|||
Echinococcus Granulosus Antigen |
|||
| NAT41602-500 | The Native Antigen Company | 0.5 | EUR 1187.13 |
|
Description: Echinococcus granulosus material is derived from bovine hydatid cyst as sterile filtered cyst fluid. |
|||
Enterovirus Antigen, Recombinant |
|||
| REC31772-100 | The Native Antigen Company | 0.1 | EUR 279.4 |
|
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus IgA, IgG and IgM ELISA. |
|||
Enterovirus Antigen, Recombinant |
|||
| REC31772-500 | The Native Antigen Company | 0.5 | EUR 1053.23 |
|
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus IgA, IgG and IgM ELISA. |
|||
Cytomegalovirus Purified Antigen |
|||
| CMV-HP-100 | The Native Antigen Company | 0.1 | EUR 321.89 |
|
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
|||
Cytomegalovirus Purified Antigen |
|||
| CMV-HP-1000 | The Native Antigen Company | 1.0 | EUR 2115.47 |
|
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
|||
Cytomegalovirus Purified Antigen |
|||
| CMV-HP-500 | The Native Antigen Company | 0.5 | EUR 1291.43 |
|
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
|||
Astrovirus Antigen (Type 1) |
|||
| AS02-1000 | The Native Antigen Company | 1.0 | EUR 1669.97 |
|
Description: A concentrated source of Astrovirus particles and Astrovirus proteins from a lysate of host cells. |
|||
Astrovirus Antigen (Type 1) |
|||
| AS02-200 | The Native Antigen Company | 0.2 | EUR 446.78 |
|
Description: A concentrated source of Astrovirus particles and Astrovirus proteins from a lysate of host cells. |
|||
Yersinia pestis V antigen |
|||
| REC32028-100 | The Native Antigen Company | 0.1 | EUR 326.34 |
|
Description: Yersinia pestis V antigen (LcrV antigen, capsule protein fraction 1, type III secretion system needle tip protein). The protein is produced as an N-terminal GST fusion, with GST being cleaved by thrombin and is not present in the final product. |
|||
Yersinia pestis V antigen |
|||
| REC32028-500 | The Native Antigen Company | 0.5 | EUR 1386.95 |
|
Description: Yersinia pestis V antigen (LcrV antigen, capsule protein fraction 1, type III secretion system needle tip protein). The protein is produced as an N-terminal GST fusion, with GST being cleaved by thrombin and is not present in the final product. |
|||
Scl-70 Antibody |
|||
| GWB-D82F78 | GenWay Biotech | 2 ml | Ask for price |
Canine Herpes Virus Antigen |
|||
| NAT41592-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Canine Herpes virus, produced in MDCK cells. |
|||
Canine Adenovirus 1 Antigen |
|||
| NAT41587-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Canine Adenovirus Type 1, produced in A-72 cells. |
|||
Canine Adenovirus 2 Antigen |
|||
| NAT41588-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Canine Adenovirus Type 2, produced in A-72 cells. |
|||
Toxoplasma gondii IgM antigen |
|||
| TG-IgM-100 | The Native Antigen Company | 0.1mg | EUR 139.86 |
|
Description: A highly purified source of Toxoplasma gondii membrane antigens, optimised for IgM detection. |
|||
Toxoplasma gondii IgM antigen |
|||
| TG-IgM-1000 | The Native Antigen Company | 1.0mg | EUR 1189.51 |
|
Description: A highly purified source of Toxoplasma gondii membrane antigens, optimised for IgM detection. |
|||
Canine Distemper Virus Antigen |
|||
| NAT41591-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Canine Distemper virus, produced in SL-29 cells. |
|||
Canine Parainfluenza Virus Antigen |
|||
| NAT41593-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Canine Parainfluenza virus antigen, produced in MDCK cells. |
|||
Feline Panleukopenia Virus Antigen |
|||
| NAT41597-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Feline Panleukopenia Virus (FPLV; feline parvovirus) antigen, produced in CRFK cells. |
|||
Norovirus GII.4 VP1 Antigen |
|||
| REC31620-100 | The Native Antigen Company | 0.1 | EUR 305.15 |
|
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
|||
Norovirus GII.4 VP1 Antigen |
|||
| REC31620-1000 | The Native Antigen Company | 1.0 | EUR 1847.65 |
|
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
|||
Norovirus GII.4 VP1 Antigen |
|||
| REC31620-500 | The Native Antigen Company | 0.5 | EUR 1076.4 |
|
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
|||
Cytomegalovirus Cell Lysate Antigen |
|||
| CMV-CL-100 | The Native Antigen Company | 0.1 | EUR 225.32 |
|
Description: A clarified cell lysate containing a mix of CMV antigens from all stages of the replication life cycle. |
|||
Cytomegalovirus Cell Lysate Antigen |
|||
| CMV-CL-1000 | The Native Antigen Company | 1.0 | EUR 1435.63 |
|
Description: A clarified cell lysate containing a mix of CMV antigens from all stages of the replication life cycle. |
|||
Feline Viral Rhinotracheitis Antigen |
|||
| NAT41598-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Feline Viral Rhinotracheitis (FVR; feline herpes virus, FHV-1) antigen, produced in CRFK cells. |
|||
Herpes Simplex Virus 1 Antigen |
|||
| HS105-1000 | The Native Antigen Company | 1.0 | EUR 1189.71 |
|
Description: HSV-1 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
|||
Herpes Simplex Virus 1 Antigen |
|||
| HS105-200 | The Native Antigen Company | 0.2 | EUR 297.43 |
|
Description: HSV-1 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
|||
Herpes Simplex Virus 2 Antigen |
|||
| HS205-1000 | The Native Antigen Company | 1.0 | EUR 1189.71 |
|
Description: HSV-2 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
|||
Herpes Simplex Virus 2 Antigen |
|||
| HS205-200 | The Native Antigen Company | 0.2 | EUR 297.43 |
|
Description: HSV-2 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
|||
Ross River Virus Recombinant Antigen |
|||
| REC31969-100 | The Native Antigen Company | 0.1 | EUR 764.81 |
|
Description: Recombinant Ross River virus antigen expressed in HEK293 cells as virus-like particles and purified by sucrose density gradients and precipitation. Virus-like particles were then solubilized in PBS containing 0.2% SDS to prevent aggregation of particles. The preparation is not particulate. Antigens in the preparation include Envelope proteins 1 and 2 and Nucleoprotein. |
|||
Ross River Virus Recombinant Antigen |
|||
| REC31969-500 | The Native Antigen Company | 0.5 | EUR 2871.26 |
|
Description: Recombinant Ross River virus antigen expressed in HEK293 cells as virus-like particles and purified by sucrose density gradients and precipitation. Virus-like particles were then solubilized in PBS containing 0.2% SDS to prevent aggregation of particles. The preparation is not particulate. Antigens in the preparation include Envelope proteins 1 and 2 and Nucleoprotein. |
|||
Canine Adenovirus 1 and 2 Antigen |
|||
| NAT41589-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: A mixture of Canine Adenovirus Type 1 and Type 2, produced in A-72 cells. |
|||
Hepatitis B Virus E Antigen (HBeAg) |
|||
| REC31677-100 | The Native Antigen Company | 0.1 | EUR 460.95 |
|
Description: Recombinant Hepititis B Virus E Protein (HBeAg). |
|||
Hepatitis B Virus E Antigen (HBeAg) |
|||
| REC31677-500 | The Native Antigen Company | 0.5 | EUR 1382.84 |
|
Description: Recombinant Hepititis B Virus E Protein (HBeAg). |
|||
Hepatitis B Virus Core Antigen (HBcAg) |
|||
| REC31689-100 | The Native Antigen Company | 0.1 | EUR 460.95 |
|
Description: Recombinant Hepititis B Virus Core Protein (HBcAg). |
|||
Hepatitis B Virus Core Antigen (HBcAg) |
|||
| REC31689-500 | The Native Antigen Company | 0.5 | EUR 1382.84 |
|
Description: Recombinant Hepititis B Virus Core Protein (HBcAg). |
|||
Hepatitis C Virus Core Antigen (HCcAg) |
|||
| REC31693-100 | The Native Antigen Company | 0.1 | EUR 489.27 |
|
Description: Recombinant Hepatitis C Virus core protein is produced in E. coli and fused with a His-tag. |
|||
Hepatitis C Virus Core Antigen (HCcAg) |
|||
| REC31693-500 | The Native Antigen Company | 0.5 | EUR 1469.11 |
|
Description: Recombinant Hepatitis C Virus core protein is produced in E. coli and fused with a His-tag. |
|||
Feline Infectious Peritonitis Virus Antigen |
|||
| NAT41596-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Feline Infectious Peritonitis virus (FIPV; feline coronavirus) antigen, produced in CRFK cells. |
|||
Herpes Simplex Virus 1 Lysate Antigen |
|||
| HS104-1000 | The Native Antigen Company | 1.0 | EUR 272.96 |
|
Description: A high concentration of HSV-1 particles and proteins from a clarified cell lysate. |
|||
Herpes Simplex Virus 2 Lysate Antigen |
|||
| HS204-1000 | The Native Antigen Company | 1.0 | EUR 272.96 |
|
Description: A high concentration of HSV-2 particles and proteins from a clarified cell lysate. |
|||
Toxoplasma gondii IgG antigen, RH strain |
|||
| TG-IgG-1000 | The Native Antigen Company | 1.0 mg | EUR 338 |
|
Description: A concentrated source of Toxoplasma gondii tachyzoite antigens, optimised for IgG detection, diluted to 0.5 mg/ml. |
|||
Toxoplasma gondii IgG antigen, RH strain |
|||
| TG-IgG-200 | The Native Antigen Company | 0.2 mg | EUR 174.83 |
|
Description: A concentrated source of Toxoplasma gondii tachyzoite antigens, optimised for IgG detection, diluted to 0.5 mg/ml. |
|||
Toxoplasma gondii IgG antigen, RH strain |
|||
| TG-IgG-5000 | The Native Antigen Company | 5.0 mg | EUR 1436.48 |
|
Description: A concentrated source of Toxoplasma gondii tachyzoite antigens, optimised for IgG detection, diluted to 0.5 mg/ml. |
|||
Legionella pneumophila antigen (native extract) |
|||
| NAT41580-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Inactivated Legionella pneumophila antigen from culture. |
|||
Streptococcus Pneumoniae Antigen, Native Extract |
|||
| NAT41604-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Inactivated Streptococcus pneumoniae antigen from culture. |
|||
Leptospira Biflexa Antigen (Strain Patoc 1) |
|||
| NAT41582-100 | The Native Antigen Company | 0.1 | EUR 395.28 |
|
Description: Inactivated Leptospira biflexa antigen (Strain Patoc 1) from broth culture. |
|||
Leptospira Biflexa Antigen (Strain Patoc 1) |
|||
| NAT41582-500 | The Native Antigen Company | 0.5 | EUR 1187.13 |
|
Description: Inactivated Leptospira biflexa antigen (Strain Patoc 1) from broth culture. |
|||
Scl-70 Ab |
|||
| DE7510 | Demeditec Diagnostics | 96 | EUR 111 |
Scl-70 ELISA |
|||
| GWB-BQK162 | GenWay Biotech | 96 Well Plate | Ask for price |
Scl-70 ELISA |
|||
| E22-HC9088 | EnoGene | 96T | EUR 495 |
Scl-70 ELISA |
|||
| MBS8579308-5x96Tests | MyBiosource | 5x96Tests | EUR 2735 |
Scl-70 ELISA |
|||
| MBS8579308-96Tests | MyBiosource | 96Tests | EUR 595 |
Mouse Anti-Hepatitis B Surface Antigen Antibody (1834) |
|||
| MAB12230-100 | The Native Antigen Company | 0.1 | EUR 278.11 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus surface antigen (1834). |
|||
Mouse Anti-Hepatitis B Surface Antigen Antibody (1837) |
|||
| MAB12231-100 | The Native Antigen Company | 0.1 | EUR 278.11 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus surface antigen (1837) |
|||
Mouse Anti-Hepatitis B Surface Antigen Antibody (1838) |
|||
| MAB12232-100 | The Native Antigen Company | 0.1 | EUR 278.11 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus surface antigen (1838) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (1892) |
|||
| MAB12226-100 | The Native Antigen Company | 0.1 | EUR 198.28 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1892) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (1893) |
|||
| MAB12227-100 | The Native Antigen Company | 0.1 | EUR 278.11 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1893) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (1894) |
|||
| MAB12228-100 | The Native Antigen Company | 0.1 | EUR 278.11 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1894) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M132) |
|||
| MAB12298-100 | The Native Antigen Company | 0.1 | EUR 279.4 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M132) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M132) |
|||
| MAB12298-500 | The Native Antigen Company | 0.5 | EUR 701.72 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M132) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M133) |
|||
| MAB12299-100 | The Native Antigen Company | 0.1 | EUR 279.4 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M133) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M133) |
|||
| MAB12299-500 | The Native Antigen Company | 0.5 | EUR 701.72 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M133) |
|||
Zika Virus Envelope Protein, Suriname Strain (SCL) |
|||
| REC31998-100 | The Native Antigen Company | 0.1 | EUR 730.05 |
|
Description: Recombinant Zika virus envelope protein expressed in HEK293 mammalian cells, with C terminal 6-His tag. |
|||
Zika Virus Envelope Protein, Suriname Strain (SCL) |
|||
| REC31998-250 | The Native Antigen Company | 0.25 | EUR 1505.16 |
|
Description: Recombinant Zika virus envelope protein expressed in HEK293 mammalian cells, with C terminal 6-His tag. |
|||
Yersinia pestis chain B F1 capsule antigen, C-terminal His-tag |
|||
| REC32027-100 | The Native Antigen Company | 0.1 | EUR 326.34 |
|
Description: Yersinia pestis chain B F1 capsule antigen (Antig_Caf1) |
|||
Yersinia pestis chain B F1 capsule antigen, C-terminal His-tag |
|||
| REC32027-500 | The Native Antigen Company | 0.5 | EUR 1386.95 |
|
Description: Yersinia pestis chain B F1 capsule antigen (Antig_Caf1) |
|||
Scl-70 ELISA Kit |
|||
| MBS580083-5x96StripWells | MyBiosource | 5x96-Strip-Wells | EUR 1150 |
Scl-70 ELISA Kit |
|||
| MBS580083-96StripWells | MyBiosource | 96-Strip-Wells | EUR 265 |
recombinant human Scl-70 |
|||
| E4A10X29 | EnoGene | 100ug | EUR 595 |
Rat Scl-70 Antibody ELISA Kit |
|||
| MBS046525-10x96StripWells | MyBiosource | 10x96-Strip-Wells | EUR 6725 |
Rat Scl-70 Antibody ELISA Kit |
|||
| MBS046525-48StripWells | MyBiosource | 48-Strip-Wells | EUR 550 |
Rat Scl-70 Antibody ELISA Kit |
|||
| MBS046525-5x96StripWells | MyBiosource | 5x96-Strip-Wells | EUR 3420 |
Rat Scl-70 Antibody ELISA Kit |
|||
| MBS046525-96StripWells | MyBiosource | 96-Strip-Wells | EUR 765 |
Cat Scl-70 Antibody ELISA Kit |
|||
| MBS098851-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Rat Scl-70 Antibody ELISA Kit |
|||
| MBS733766-10x96StripWells | MyBiosource | 10x96-Strip-Wells | EUR 5685 |
Rat Scl-70 Antibody ELISA Kit |
|||
| MBS733766-48StripWells | MyBiosource | 48-Strip-Wells | EUR 485 |
Rat Scl-70 Antibody ELISA Kit |
|||
| MBS733766-5x96StripWells | MyBiosource | 5x96-Strip-Wells | EUR 3020 |
Rat Scl-70 Antibody ELISA Kit |
|||
| MBS733766-96StripWells | MyBiosource | 96-Strip-Wells | EUR 690 |
Duck Scl-70 Antibody ELISA Kit |
|||
| MBS064027-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Goat Scl-70 Antibody ELISA Kit |
|||
| MBS005211-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Cavy Scl-70 Antibody ELISA Kit |
|||
| MBS042029-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Fish Scl-70 Antibody ELISA Kit |
|||
| MBS044490-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Goat Scl-70 Antibody ELISA Kit |
|||
| MBS745982-10x96StripWells | MyBiosource | 10x96-Strip-Wells | EUR 5685 |
Goat Scl-70 Antibody ELISA Kit |
|||
| MBS745982-48StripWells | MyBiosource | 48-Strip-Wells | EUR 485 |
Goat Scl-70 Antibody ELISA Kit |
|||
| MBS745982-5x96StripWells | MyBiosource | 5x96-Strip-Wells | EUR 3020 |
Goat Scl-70 Antibody ELISA Kit |
|||
| MBS745982-96StripWells | MyBiosource | 96-Strip-Wells | EUR 690 |
Camel Scl-70 Antibody ELISA Kit |
|||
| MBS077184-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Goose Scl-70 Antibody ELISA Kit |
|||
| MBS033457-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Horse Scl-70 Antibody ELISA Kit |
|||
| MBS043959-10x96StripWells | MyBiosource | 10x96-Strip-Wells | EUR 6725 |
Horse Scl-70 Antibody ELISA Kit |
|||
| MBS043959-48StripWells | MyBiosource | 48-Strip-Wells | EUR 550 |
Horse Scl-70 Antibody ELISA Kit |
|||
| MBS043959-5x96StripWells | MyBiosource | 5x96-Strip-Wells | EUR 3420 |
Horse Scl-70 Antibody ELISA Kit |
|||
| MBS043959-96StripWells | MyBiosource | 96-Strip-Wells | EUR 765 |
Mouse Scl-70 Antibody ELISA Kit |
|||
| MBS035621-10x96StripWells | MyBiosource | 10x96-Strip-Wells | EUR 6725 |
Mouse Scl-70 Antibody ELISA Kit |
|||
| MBS035621-48StripWells | MyBiosource | 48-Strip-Wells | EUR 550 |
Mouse Scl-70 Antibody ELISA Kit |
|||
| MBS035621-5x96StripWells | MyBiosource | 5x96-Strip-Wells | EUR 3420 |
Mouse Scl-70 Antibody ELISA Kit |
|||
| MBS035621-96StripWells | MyBiosource | 96-Strip-Wells | EUR 765 |
Sheep Scl-70 Antibody ELISA Kit |
|||
| MBS035116-10x96StripWells | MyBiosource | 10x96-Strip-Wells | EUR 6725 |
Sheep Scl-70 Antibody ELISA Kit |
|||
| MBS035116-48StripWells | MyBiosource | 48-Strip-Wells | EUR 550 |
Sheep Scl-70 Antibody ELISA Kit |
|||
| MBS035116-5x96StripWells | MyBiosource | 5x96-Strip-Wells | EUR 3420 |
Sheep Scl-70 Antibody ELISA Kit |
|||
| MBS035116-96StripWells | MyBiosource | 96-Strip-Wells | EUR 765 |
Human Scl-70 Antibody ELISA Kit |
|||
| MBS021013-10x96StripWells | MyBiosource | 10x96-Strip-Wells | EUR 6725 |
Human Scl-70 Antibody ELISA Kit |
|||
| MBS021013-48StripWells | MyBiosource | 48-Strip-Wells | EUR 550 |
Human Scl-70 Antibody ELISA Kit |
|||
| MBS021013-5x96StripWells | MyBiosource | 5x96-Strip-Wells | EUR 3420 |
Human Scl-70 Antibody ELISA Kit |
|||
| MBS021013-96StripWells | MyBiosource | 96-Strip-Wells | EUR 765 |
Human Scl-70 Antibody ELISA Kit |
|||
| MBS731454-10x96StripWells | MyBiosource | 10x96-Strip-Wells | EUR 5685 |
Human Scl-70 Antibody ELISA Kit |
|||
| MBS731454-48StripWells | MyBiosource | 48-Strip-Wells | EUR 485 |
Human Scl-70 Antibody ELISA Kit |
|||
| MBS731454-5x96StripWells | MyBiosource | 5x96-Strip-Wells | EUR 3020 |
Human Scl-70 Antibody ELISA Kit |
|||
| MBS731454-96StripWells | MyBiosource | 96-Strip-Wells | EUR 690 |
Mouse Scl-70 Antibody ELISA Kit |
|||
| MBS726620-10x96StripWells | MyBiosource | 10x96-Strip-Wells | EUR 5685 |
Mouse Scl-70 Antibody ELISA Kit |
|||
| MBS726620-48StripWells | MyBiosource | 48-Strip-Wells | EUR 485 |
Mouse Scl-70 Antibody ELISA Kit |
|||
| MBS726620-5x96StripWells | MyBiosource | 5x96-Strip-Wells | EUR 3020 |
Mouse Scl-70 Antibody ELISA Kit |
|||
| MBS726620-96StripWells | MyBiosource | 96-Strip-Wells | EUR 690 |
Sheep Scl-70 Antibody ELISA Kit |
|||
| MBS749914-10x96StripWells | MyBiosource | 10x96-Strip-Wells | EUR 5685 |
Sheep Scl-70 Antibody ELISA Kit |
|||
| MBS749914-48StripWells | MyBiosource | 48-Strip-Wells | EUR 485 |
Sheep Scl-70 Antibody ELISA Kit |
|||
| MBS749914-5x96StripWells | MyBiosource | 5x96-Strip-Wells | EUR 3020 |
Sheep Scl-70 Antibody ELISA Kit |
|||
| MBS749914-96StripWells | MyBiosource | 96-Strip-Wells | EUR 690 |
Donkey Scl-70 Antibody ELISA Kit |
|||
| MBS091123-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Pigeon Scl-70 Antibody ELISA Kit |
|||
| MBS058163-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Monkey Scl-70 Antibody ELISA Kit |
|||
| MBS042947-10x96StripWells | MyBiosource | 10x96-Strip-Wells | EUR 6725 |
Monkey Scl-70 Antibody ELISA Kit |
|||
| MBS042947-48StripWells | MyBiosource | 48-Strip-Wells | EUR 550 |
Monkey Scl-70 Antibody ELISA Kit |
|||
| MBS042947-5x96StripWells | MyBiosource | 5x96-Strip-Wells | EUR 3420 |
Monkey Scl-70 Antibody ELISA Kit |
|||
| MBS042947-96StripWells | MyBiosource | 96-Strip-Wells | EUR 765 |
CD4 + T Cells of Prostate Most cancers Sufferers Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 Spike Glycoprotein
The adaptive immune response to extreme acute respiratory coronavirus 2 (SARS-CoV-2) is essential for vaccine growth and within the restoration from coronavirus illness 2019 (COVID-19). Males and most cancers sufferers have been reported to be at greater dangers of contracting the virus and creating the extra extreme types of COVID-19. Prostate most cancers (PCa) could also be related to each of those dangers. We present that CD4+ T cells of SARS-CoV-2-unexposed sufferers with hormone-refractory (HR) metastatic PCa had decreased CD4+ T cell immune responses to antigens from SARS-CoV-2 spike glycoprotein however not from the spiked glycoprotein of the ‘frequent chilly’-associated human coronavirus 229E (HCoV-229E) as in contrast with wholesome male volunteers who responded comparably to each HCoV-229E- and SARS-CoV-2-derived antigens.
Furthermore, the HCoV-229E spike glycoprotein antigen-elicited CD4+ T cell immune responses cross-reacted with the SARS-CoV-2 spiked glycoprotein antigens. PCa sufferers might have impaired responses to the vaccination, and the cross-reactivity can mediate antibody-dependent enhancement (ADE) of COVID-19. These findings spotlight the potential for elevated vulnerability of PCa sufferers to COVID-19.
Circulating SARS-CoV-2 Vaccine Antigen Detected within the Plasma of mRNA-1273 Vaccine Recipients
SARS-CoV-2 proteins had been measured in longitudinal plasma samples collected from 13 individuals who obtained two doses of mRNA-1273 vaccine. 11 of 13 individuals confirmed detectable ranges of SARS-CoV-2 protein as early as day one after first vaccine injection. Clearance of detectable SARS-CoV-2 protein correlated with manufacturing of IgG and IgA.
Characterizing Prostate-Particular Antigen Ranges at Dying in Sufferers with Metastatic Castration-Resistant Prostate Most cancers: Are We Underutilizing Imaging?
Background: Prostate-specific antigen (PSA) is a beneficial prognostic and predictive biomarker in prostate most cancers; nevertheless, the importance of PSA at or close to the time of demise isn’t properly understood. This examine aimed to characterize the importance of PSA at demise in sufferers with metastatic castration-resistant prostate most cancers (mCRPC).
Sufferers and strategies: The Mount Sinai Genitourinary Most cancers Biorepository, an institutional overview board-approved, single-institution database containing all consented genitourinary most cancers sufferers seen between 2010 and 2018, was used to determine and stratify sufferers into the next cohorts based mostly on their PSA at or close to demise: <100 ng/mL, 100-1000 ng/mL, and >1000 ng/mL. Analyses had been carried out to evaluate medical traits of illness, remedy response, and outcomes.
Outcomes: We recognized 1097 sufferers with prostate most cancers, and 101 had been confirmed to be deceased following a prognosis of mCRPC. In sufferers with mCRPC, cohorts of upper PSA degree at demise had been related to decrease Gleason rating at prognosis and a pattern towards longer time to mCRPC and longer time from prognosis to demise, regardless of the next burden of illness at demise. Conversely, subgroup evaluation of PSA < 10 ng/mL at demise was related to decrease charges of imaging inside 6 months of demise, decrease remedy charge, and worse medical outcomes.
Conclusions: Cohorts of various PSA ranges at demise in mCRPC sufferers confirmed distinct patterns of illness traits and medical outcomes, possible as a result of underlying molecular phenotype variations. Imaging for the affected person inhabitants with very low PSA ranges could also be underutilized and needs to be thought-about extra routinely.
Actual-world medical efficiency of economic SARS-CoV-2 speedy antigen exams in suspected COVID-19: A scientific meta-analysis of obtainable knowledge as per November 20, 2020
Goals: Speedy antigen exams, or RATs, are a sort of lateral move chromatographic immunoassay which have been utilized to assist prognosis of SARS-CoV-2 an infection. We carried out a scientific meta-analysis to check the real-world efficiency of commercially obtainable RATs.
Strategies: We searched a number of databases and web sites for manufacturer-independent potential medical efficiency research evaluating SARS-CoV-2 RATs and RT-PCR. Solely research on RATs that didn’t want a separate reader for end result retrieval and that reported knowledge on viral load, sufferers’ symptom standing, pattern kind, and PCR assay used had been included.
Outcomes: 19 research using 11,109 samples with 2,509 RT-PCR-positives had been included. RAT sensitivity various between 28.9% (95% CI 16.4-44.3) and 98.3% (95% CI 91.1-99.7), possible dependent upon inhabitants traits, viral load, and symptom standing. RAT specificity various between 92.4% (95% CI 87.4-95.9) and 100% (95% CI 99.7-100) with one outlier. The RATs by Roche Diagnostics/SD Biosensor and Abbott had the very best pooled sensitivity (82.4% [95% CI 74.2-88.4] and 76.9% [95% CI 72.1-81.2], respectively). Sensitivity in high-viral-load samples (cycle threshold ≤25) confirmed heterogeneity among the many totally different RATs.
Conclusion: The RATs provided by Roche Diagnostics/SD Biosensor and Abbott present ample manufacturer-independent, real-world efficiency knowledge to help their use for detection of present SARS-CoV-2 an infection, notably in high-viral-load populations.
